Since the results demonstrated that on-admission albumin levels predicted <30 days all-cause mortality in confirmed COVID-19 patients, and that this was affected by on-admission glucose levels, additional in vitro experiments were performed to analyze the possibility that native albumin and/or glycated albumin may bind the SARS-CoV-2 spike S1 and S2 subunits. The gene discussed is ALB; the disease is COVID-19.